Back to Search Start Over

Risk Analysis of Respiratory Syncytial Virus Among Infants in the United States by Birth Month.

Authors :
Gantenberg JR
van Aalst R
Bhuma MR
Limone B
Diakun D
Smith DM
Nelson CB
Bengtson AM
Chaves SS
La Via WV
Rizzo C
Savitz DA
Zullo AR
Source :
Journal of the Pediatric Infectious Diseases Society [J Pediatric Infect Dis Soc] 2024 Jun 28; Vol. 13 (6), pp. 317-327.
Publication Year :
2024

Abstract

Background: Respiratory syncytial virus (RSV) is a major cause of morbidity and mortality among US infants. A child's calendar birth month determines their age at first exposure(s) to RSV. We estimated birth month-specific risk of medically attended (MA) RSV lower respiratory tract infection (LRTI) among infants during their first RSV season and first year of life (FYOL).<br />Methods: We analyzed infants born in the USA between July 2016 and February 2020 using three insurance claims databases (two commercial, one Medicaid). We classified infants' first MA RSV LRTI episode by the highest level of care incurred (outpatient, emergency department, or inpatient), employing specific and sensitive diagnostic coding algorithms to define index RSV diagnoses. In our main analysis, we focused on infants' first RSV season. In our secondary analysis, we compared the risk of MA RSV LRTI during infants' first RSV season to that of their FYOL.<br />Results: Infants born from May through September generally had the highest risk of first-season MA RSV LRTI-approximately 6-10% under the specific RSV index diagnosis definition and 16-26% under the sensitive. Infants born between October and December had the highest risk of RSV-related hospitalization during their first season. The proportion of MA RSV LRTI events classified as inpatient ranged from 9% to 54% (specific) and 5% to 33% (sensitive) across birth month and comorbidity group. Through the FYOL, the overall risk of MA RSV LRTI is comparable across birth months within each claims database (6-11% under the specific definition, 17-30% under the sensitive), with additional cases progressing to care at outpatient or ED settings.<br />Conclusions: Our data support recent national recommendations for the use of nirsevimab in the USA. For infants born at the tail end of an RSV season who do not receive nirsevimab, a dose administered prior to the onset of their second RSV season could reduce the incidence of outpatient- and ED-related events.<br /> (© The Author(s) 2024. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society.)

Details

Language :
English
ISSN :
2048-7207
Volume :
13
Issue :
6
Database :
MEDLINE
Journal :
Journal of the Pediatric Infectious Diseases Society
Publication Type :
Academic Journal
Accession number :
38738450
Full Text :
https://doi.org/10.1093/jpids/piae042